Zeelab targets ₹200 Cr FY27 revenue as it scales 300-store omnichannel pharmacy network

Zeelab Pharmacy is expanding its company-owned network, using compact stores as sales, trust and hyperlocal fulfilment hubs. The chain says it generated about ₹110 Cr in FY26 operating revenue, with online and offline each contributing roughly half, and plans 60-minute delivery across about 30 cities.

— Source publishedSun, 6 Sept, 2026, 10:00 IST·First seen Sun, 6 Sept, 2026, 10:28 IST·Source Inc42 · Buzz

What happened

Zeelab Pharmacy is scaling its company-owned omnichannel network after abandoning franchising, with more than 300 stores serving as sales, trust and fulfilment

Key facts

  • More than 300 stores
  • Around 10,000 orders per day
  • ₹110 Cr operating revenue in FY26
  • ₹200 Cr revenue target in FY27
  • Around 200 sq ft typical store size
  • Online and offline channels each contribute roughly 50% of revenue
  • 60-minute medicine delivery planned across approximately 30 cities
  • July 2026 revenue was 100% higher than July 2025
  • ₹150 branded diclofenac gel versus ₹25 Zeelab equivalent

Why this matters

Zeelab’s expanding owned-store footprint and hyperlocal delivery capability could make it a relevant partnership or acquisition target for healthcare, quick-commerce and retail platforms seeking pharmacy distribution density.

What to watch

  • Number of company-owned stores opened, closures and average stores per city.
  • Evidence that FY27 revenue run rate is approaching ₹200 Cr without disproportionate discounting.
  • Online share of revenue, repeat-order rates and 60-minute delivery serviceability by city.
  • Store-level revenue productivity, contribution margin and payback period.
  • Generic and private-label mix, average basket value and chronic-care customer retention.
  • Capital raised or debt added to finance inventory, store buildout and delivery operations.
  • Competitive discounting or quick-commerce entry into prescription and OTC medicine delivery.
  • Regulatory developments affecting e-pharmacy operations, prescription verification or medicine delivery.
  • Prioritize store clusters in high prescription-frequency neighborhoods rather than broad city-by-city rollout.
  • Use stores as micro-fulfillment nodes with city-level inventory pooling to reduce stock-outs and delivery expense.
  • Increase generic substitution, private-label penetration and chronic-care refill programs to protect margins.
  • Build doctor, clinic, diagnostic-lab and corporate-health partnerships to create recurring prescription demand.
  • Track store-level contribution margin separately from online GMV to prevent rapid-delivery growth from masking weak unit economics.
  • Standardize compliance, pharmacist availability and cold-chain processes before entering additional cities.

Also reported by